Target $4
Monday, July 10, 2023
Jupiter Wellness Acquires World’s 1st Rapid Blood Alcohol Detox Drink “Safety Shot” to Launch Q4
Asset valued at $53 million by a third party Valuation firm
Jupiter Wellness, Inc. (Nasdaq: JUPW), a diversified company that supports health and wellness, today announced it has executed an Asset Purchase Agreement with GBB Drink Lab Inc.. As per the Agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness, Safety Shot creates a new product category for rapid alcohol detoxification in the fast-growing hangover remedy market. Safety Shot is protected by a number of issued and pending patents covering composition of matter and methods of use.
Created by a doctor and validated by research, Safety Shot helps your body break down alcohol faster while aiding in recovery and rehydration. The product is formulated with scientifically proven ingredients that stop your body from absorbing alcohol into your blood, reducing your Blood Alcohol Content (BAC) and getting you out of an intoxicated state.
Consumers are now more aware of the benefits associated with the consumption of hangover cure products, which help improve metabolism, reduce nausea caused due to excessive alcohol consumption, and can hydrate the body.
The global hangover cure products market size is expected to reach USD 4.67 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 14.6% from 2021 to 2028.
The Safety Shot business segment alone is forecasted to produce approximately $25 million in revenues and $4 million in net income by first quarter of 2024 for Jupiter Wellness with accelerated top and bottom-line contributions thereafter. There can be no assurances that we will reach such sales levels or profits. Jupiter Wellness believes that it is well-funded and has the capability to take the purchased patents and provisional patents from the Company and bring them to market. Jupiter will deploy a multi-channel strategy designed to dominate e-commerce and quickly win retail shelf space.
Inflammatory disease biotech Apogee Therapeutics sets terms for $250 million IPO
Apogee Therapeutics, a Phase 1-ready biotech developing monoclonal antibodies for inflammatory diseases, announced terms for its IPO on Monday.
The Waltham, MA-based company plans to raise $250 million by offering 15.6 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Apogee Therapeutics would command a fully diluted market value of $735 million.
Founded by healthcare investors Fairmount Funds and Venrock, Apogee Therapeutics is developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications with high unmet need. Its two most advanced programs, APG777 and APG808, are subcutaneous extended half-life monoclonal antibodies initially being developed for AD and COPD, respectively. The company anticipates initiating a Phase 1 trial of APG777 in the 2H23, with initial data expected in mid-2024, and anticipates nominating a development candidate for its APG808 program in 2023. Apogee has exclusive development and commercialization rights to its programs through a strategic collaboration with Paragon Therapeutics, a biotech founded in 2021 by Fairmount Funds.
Apogee Therapeutics was founded in 2022 and plans to list on the Nasdaq under the symbol APGE. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price during the week of July 10, 2023.
ImmunityBio Phase 1: Natural Killer Cells Plus N-803 May Induce Tumor Regression
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced findings from a Phase 1 study showing that allogeneic cytokine-induced memory-like (CIML) natural killer (NK) cells used in combination with ImmunityBio’s IL-15 superagonist N-803 may induce tumor regression associated with persistent CIML NK cell expansion in advanced head-and-neck cancer patients. The results indicate the potential for a new treatment approach for the disease in advanced cases that currently have extremely poor prognoses.
The data from the proof-of-concept study were presented by Glenn J. Hanna, M.D., Medical Oncologist with Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School at the American Association for Cancer Research (AACR) and the American Head and Neck Society (AHNS) joint conference in Montreal, July 7-8, 2023.
Patients with recurrent incurable or metastatic (R/M) head and neck cancers (HNCs) that do not respond to platinum chemotherapy and immunotherapy have poor survival rates. Cellular therapies have emerged as treatments with potential activity in solid tumors.
https://finance.yahoo.com/news/phase-1-study-indicates-allogeneic-133000260.html
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
Fulcrum Therapeutics, Inc.® (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp., whereby Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).
DBA is a congenital, rare blood disorder that affects an estimated 5,000 individuals worldwide. DBA is caused by genetic mutations in ribosomal subunits that halt red blood cell maturation and lead to anemia. Patients are usually diagnosed in infancy with the presentation of severe anemia and potential developmental abnormalities. Patients with DBA require lifelong management with corticosteroids and blood transfusions that are known for their toxicities and long-term complications.
HCA Healthcare Reports Data Security Incident
HCA Healthcare, Inc. (NYSE:HCA) recently discovered that a list of certain information with respect to some of its patients was made available by an unknown and unauthorized party on an online forum. The list includes:
Patient name, city, state, and zip code;
Patient email, telephone number, date of birth, gender; and
Patient service date, location and next appointment date.
HCA Healthcare has confirmed that the list contains information used for email messages, such as reminders that patients may wish to schedule an appointment and education on healthcare programs and services.
Importantly, the list does not include:
Clinical information, such as treatment, diagnosis, or condition;
Payment information, such as credit card or account numbers;
Sensitive information, such as passwords, driver’s license or social security numbers.
This appears to be a theft from an external storage location exclusively used to automate the formatting of email messages. There has been no disruption to the care and services HCA Healthcare provides to patients and communities. This incident has not caused any disruption to the day-to-day operations of HCA Healthcare. Based on the information known at this time, the company does not believe the incident will materially impact its business, operations or financial results.
HCA Healthcare reported this event to law enforcement and retained third-party forensic and threat intelligence advisors. While our investigation is ongoing, the company has not identified evidence of any malicious activity on HCA Healthcare networks or systems related to this incident. The company disabled user access to the storage location as an immediate containment measure and plans to contact any impacted patients to provide additional information and support, in accordance with its legal and regulatory obligations, and will offer credit monitoring and identity protection services, where appropriate.
HCA Healthcare believes the privacy of its patients is a vital part of its mission and remains committed to maintaining the security of their personal information. HCA Healthcare has created a dedicated webpage at hcahealthcare.com/privacyupdate to keep its patients informed.
Eloxx to Target the Human Ribosome for Therapeutic Benefit
Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications
Results suggest that MYC overexpressing cancers can be targeted by exploiting ribosome heterogeneity in cancer; preclinical data demonstrated activity of ZKN-157 against subtypes of colorectal cancer
Research potentially opens large opportunities to selectively target MYC-driven cancers with a novel mechanism and possible synergy with existing cancer therapies
Subscribe to:
Comments (Atom)